1. Bioinformatics approach combined with experimental verification reveals OAS3 gene implicated in paclitaxel resistance in head and neck cancer.
- Author
-
Caglar HO, Aytatli A, Barlak N, Aydin Karatas E, Tatar A, Sahin A, and Karatas OF
- Subjects
- Humans, Cell Line, Tumor, Squamous Cell Carcinoma of Head and Neck genetics, Squamous Cell Carcinoma of Head and Neck drug therapy, Squamous Cell Carcinoma of Head and Neck pathology, Antineoplastic Agents, Phytogenic pharmacology, Antineoplastic Agents, Phytogenic therapeutic use, Gene Expression Regulation, Neoplastic, Apoptosis drug effects, Apoptosis genetics, 2',5'-Oligoadenylate Synthetase genetics, Male, Female, Cell Survival drug effects, Cell Survival genetics, Middle Aged, Paclitaxel pharmacology, Paclitaxel therapeutic use, Drug Resistance, Neoplasm genetics, Head and Neck Neoplasms genetics, Head and Neck Neoplasms drug therapy, Head and Neck Neoplasms pathology, Computational Biology, Carcinoma, Squamous Cell genetics, Carcinoma, Squamous Cell drug therapy, Carcinoma, Squamous Cell pathology
- Abstract
Background: This study aimed to identify a candidate gene associated with paclitaxel (PTX) resistance and to evaluate functionally its biological role in the PTX-resistant head and neck squamous cell carcinoma (HNSCC) cell lines and clinical specimens., Methods: Microarray data series containing samples of different types of cancers resistant to PTX were analyzed and then a candidate gene associated with PTX resistance was identified using various bioinformatics tools. After the suppression of the target gene expression, changes in cell viability and colony-forming ability were evaluated in PTX-resistant FaDu and SCC-9 cell lines., Results: Bioinformatics analyses of upregulated genes in PTX-resistant cancer cells indicated that OAS3 was associated with PTX resistance. The downregulation of OAS3 expression significantly reduced the viability and colony-forming capacity of PTX-resistant SCC-9 cells by inducing apoptosis and cell cycle arrest at G0/G1 phase., Conclusions: The therapeutic targeting of OAS3 may resensitize PTX-resistant HNSCC cells with high OAS3 expression to PTX treatment., (© 2024 The Authors. Head & Neck published by Wiley Periodicals LLC.)
- Published
- 2024
- Full Text
- View/download PDF